



- (51) **International Patent Classification:**
A61K 39/145 (2006.01) *C12N 15/44* (2006.01)
- (21) **International Application Number:**
PCT/US2011/066867
- (22) **International Filing Date:**
22 December 2011 (22.12.2011)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/426,390 22 December 2010 (22.12.2010) US
- (71) **Applicant** (*for all designated States except US*):
NOVAVAX INC. [US/US]; 9920 Belward Campus Drive,
Rockville, Maryland 20850 (US).
- (72) **Inventors; and**
- (75) **Inventors/Applicants** (*for US only*): **SMITH, Gale**
[US/US]; c/o NOVAVAX INC., 9920 Belward Campus
Drive, Rockville, Maryland 20850 (US). **LIU, Ye**
[US/US]; c/o NOVAVAX INC., 9920 Belward Campus
Drive, Rockville, Maryland 20850 (US). **MASSARE, Mi-**
chael [US/US]; c/o NOVAVAX INC., 9920 Belward Cam-
pus Drive, Rockville, Maryland 20850 (US). **SINGHVI,**
Rahul [US/US]; c/o NOVAVAX INC., 9920 Belward
Campus Drive, Rockville, Maryland 20850 (US).
- (74) **Agents:** TUSCAN, Michael S. et al.; COOLEY LLP, 777
6th Street, N.W., Suite 1100, Washington, District of
Columbia 20001 (US).

- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** MODIFIED INFLUENZA HEMAGGLUTININ PROTEINS AND USES THEREOF

(57) **Abstract:** The present invention is generally directed to modified influenza hemagglutinin (HA) proteins and methods for making and using them, including their use in immunogenic compositions such as vaccines for the treatment and/or prevention of influenza infection.



WO 2012/088428 A1